SCHEMBL11998005

SCHEMBL11998005

COC(=O)c1cc(C(=O)CO)cc(-c2ccccn2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 1/20 0.49
GRM5 P41594 2/20 0.47
KAT6A Q92794 2/20 0.44
TGFBR1 P36897 1/20 0.44
KDM5B Q9UGL1 1/20 0.44
NPC1 O15118 1/20 0.43
HPGD P15428 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
KDM4E B2RXH2 4/20 0.43
GABRA5 P31644 2/20 0.43
KDM6B O15054 1/20 0.43
KDM5C P41229 1/20 0.43
KDM4C Q9H3R0 1/20 0.43
KDM2A Q9Y2K7 1/20 0.43
KDM3A Q9Y4C1 1/20 0.43
TSHR P16473 1/20 0.42
PKM P14618 1/20 0.42
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL475480 0.90 AXL (0.56) AXLGRM5KAT6ATGFBR1KDM4E
SCHEMBL989567 0.87 AXL (0.56) AXLGRM5KAT6ATGFBR1KDM4E
SCHEMBL5562975 0.82 GRM5 (0.64) AXLGRM5KAT6ATGFBR1KDM4E
SCHEMBL11998006 0.82 ALDH1A1 (0.43) RAB9AKDM4EGABRA5KDM6BKDM5C
SCHEMBL3554650 0.82 AXL (0.52) AXLGRM5KAT6ATGFBR1KDM5B
SCHEMBL4542026 0.81 AXL (0.51) AXLGRM5KAT6ATGFBR1KDM4E
SCHEMBL3556217 0.81 AXL (0.51) AXLGRM5KAT6ATGFBR1NPC1
SCHEMBL18718093 0.78 CA12 (0.54) KDM4ETSHRPOLBMAPTALDH1A1
SCHEMBL30772298 0.77 TGFBR1 (0.60) AXLTGFBR1NPC1RAB9ASMN1; SMN2
SCHEMBL6259 0.77 TGFBR1 (0.60) AXLTGFBR1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130102593-A1 PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF PURDUE RESEARCH FOUNDATION 2013-04-25 US disclosed
US-20130059840-A1 SULFONAMIDO PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF COMENTIS, INC. (US) 2013-03-07 US disclosed
US-20120295894-A1 PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF BILCER GEOFFREY M (US) 2012-11-22 US disclosed
US-20120214802-A1 PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF PURDUE RESEARCH FOUNDATION 2012-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059840-A1 SULFONAMIDO PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF BACE1, BACE2, GSAP AXL 3497/4885GRM5 1782/4885KAT6A 3990/4885
US-20120295894-A1 PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF BACE1, BACE2, APP AXL 4769/4885GRM5 1333/4885KAT6A 3421/4885
US-20120214802-A1 PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF BACE1, BACE2, APP AXL 4769/4885GRM5 1333/4885KAT6A 3421/4885
US-20130102593-A1 PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF BACE1, BACE2, APP AXL 4769/4885GRM5 1333/4885KAT6A 3421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.